Browse > Article

Venlafaxine-Induced Acute Toxic Hepatitis  

Na, Kyeong-Sae (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital)
Hwang, Hee-Sung (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital)
Kim, Shin-Gyeom (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital)
Lee, So-Young-Irene (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital)
Jung, Han-Yong (Department of psychiatry, College of Medicine, Soonchunhyang University Bucheon Hospital)
Publication Information
Korean Journal of Biological Psychiatry / v.18, no.3, 2011 , pp. 159-162 More about this Journal
Abstract
Venlafaxine is among the most widely prescribed antidepressants. It is extensively metabolized to O-desmethylvenlafaxine via cytochrome P450 (CYP) 2D6. We report a case of acute toxic hepatitis resulting from venlafaxine in a 54-year-old woman with pain disorder. During venlafaxine treatment, laboratory tests revealed elevated liver enzymes with a maximum of 169 IU/L for aspartate transaminase (AST) and 166 IU/L for alanine transaminase (ALT). AST and ALT levels returned to normal after 6 days of discontinuation of venlafaxine. The patient was finally diagnosed with acute toxic hepatitis through liver biopsy. This case indicates the importance that clinicians should be aware of the hepatotoxicity of venlafaxine in practice.
Keywords
Venlafaxine; Drug-induced liver injury; Antidepressant; Drug toxicity;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003;10:318-323.   DOI   ScienceOn
2 Lithner F. Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. Diabetes Care 2000;23:1710-1711.   DOI   ScienceOn
3 Pernia A, Mico JA, Calderon E, Torres LM. Venlafaxine for the treatment of neuropathic pain. J Pain Symptom Manage 2000;19:408-410.   DOI   ScienceOn
4 Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998;51:237-254.   DOI   ScienceOn
5 Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-59S; discussion 59S-61S.   DOI
6 Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis. Ann Intern Med 2000;132:417.
7 Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis. Ann Intern Med 1999;130:944.
8 Phillips BB, Digmann RR, Beck MG. Hepatitis associated with lowdose venlafaxine for postmenopausal vasomotor symptoms. Ann Pharmacother 2006;40:323-327.   DOI   ScienceOn
9 Pradeep RJ, Victor G, Iby N, Kurpad SS, Galgali RB, Srinivasan K. Venlafaxine induced hepatitis. J Assoc Physicians India 2004;52:340.
10 Sencan I, Sahin I, Ozcetin A. Low-dose venlafaxine-associated liver toxicity in chronic hepatitis. Ann Pharmacother 2004;38:352-353.
11 Detry O, Delwaide J, De Roover A, Hans MF, Delbouille MH, Monard J, et al. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report. ransplant Proc 2009;41:3435-3436.
12 Ostapowicz G, Fontana RJ, SchiOdt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.   DOI   ScienceOn
13 Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-226.   DOI   ScienceOn
14 Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002;287:2273-2275.   DOI   ScienceOn
15 Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001;24:483-490.   DOI   ScienceOn
16 Chitturi S, Farrell GC. Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 2000;15:1093-1099.   DOI   ScienceOn
17 Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-310.   DOI   ScienceOn
18 Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485.   DOI   ScienceOn
19 Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007;13:329-340.   DOI
20 Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.   DOI   ScienceOn
21 Kim DJ. The assessment of toxic liver injury. Korean J Gastroenterol 2009;53:5-14.
22 Sadock BJ, Sadock VA. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Philadelphia: Lippincott Williams & Wilkins;2005. p.2781-2788.
23 Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-3053.   DOI   ScienceOn
24 Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000;12 Suppl 1:30-44.
25 Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-177.   DOI   ScienceOn
26 Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502.   DOI   ScienceOn
27 Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009;29:39-43.   DOI   ScienceOn
28 Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 2002;17 Suppl 1:S25-S35.   DOI
29 Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010;32:1174-1183. doi: 10.1111/j.1365-2036.2010.04449.x.   DOI   ScienceOn
30 Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294.   DOI   ScienceOn
31 Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999;19:427-442.   DOI   ScienceOn
32 Courtney DB. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry 2004;49:557-563.   DOI
33 Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2002:24-30.
34 Dierick M. A review of the efficacy and tolerability of venlafaxine. Eur Psychiatry 1997;12 Suppl 4:307s-313s.   DOI